Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TaiMed BiologicsROCO:4147 -3.83%63 Cash Ratio is 8.13 as of Jun. 2026, which is 16% above its 10-year median of 7.02. GuruFocus rates ROCO:4147 with a GF Score™ of 63/100 and a GF Value™ of NT$80.51 (Modestly Undervalued). Among 1,382 Biotechnology companies, TaiMed Biologics ranks better than 74.96% on this metric.
TaiMed Biologics (ROCO:4147) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
TaiMed Biologics Cash Ratio Related Terms
TaiMed Biologics Cash Ratio Historical Data
* Premium members only.
The historical data trend for TaiMed Biologics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4147 vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, TaiMed Biologics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiMed Biologics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiMed Biologics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where TaiMed Biologics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiMed Biologics (ROCO:4147) has a Cash Ratio of 8.13 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on TaiMed Biologics and its competitors. This is 16% above median its historical median of 7.02. Over the past decade, TaiMed Biologics' Cash Ratio has ranged from 1.60 to 268.68. According to the industry distribution chart, TaiMed Biologics ranks #346 out of 1382 companies in the Biotechnology industry, placing it in the top 25%.
Is TaiMed Biologics' Cash Ratio too high?
TaiMed Biologics' current Cash Ratio of 8.13 is 16% above median its 10-year median of 7.02. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 268.68. The Biotechnology industry median Cash Ratio is 2.93. TaiMed Biologics' value of 8.13 is 177.5% above this industry median. Based on the distribution chart, TaiMed Biologics ranks #346 out of 1382 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TaiMed Biologics has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #346 out of 1382 companies for Cash Ratio. This places TaiMed Biologics in the top 25% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. TaiMed Biologics' value of 8.13 is 177.5% above this benchmark. Historically, TaiMed Biologics' own Cash Ratio has ranged from 1.60 to 268.68 over the past decade. While the company's 10-year median is 7.02 vs. the industry median of 2.93, TaiMed Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TaiMed Biologics's current Cash Ratio of 8.13 is 177.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on TaiMed Biologics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiMed Biologics's current Cash Ratio is 8.13, which is 16% above median its own 10-year median of 7.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$80.51, compared to a current price of NT$62.80 — trading 22% below its estimated fair value. The current Cash Ratio is 8.13, which is 16% above median its 10-year median of 7.02 and 177.5% above the Biotechnology industry median of 2.93. TaiMed Biologics' overall GF Score™ is 63/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current Cash Ratio is 8.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?
Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued.
The current stock price of NT$62.80 is trading 22% below its estimated GF Value™ of NT$80.51.
GuruFocus considers TaiMed Biologics to be Modestly Undervalued.
Key valuation signals for ROCO:4147:
Cash Ratio: 8.13 (16% above median its 10-year median of 7.02)
GF Value™: NT$80.51 vs. price of NT$62.80 (22% below fair value)
Industry Position: 177.5% above the Biotechnology median (#346 of 1382)
No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
63GF Score
Get the complete analysis for ROCO:4147
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4147 has been successfully added to your 
